Neuralink is making its case for a brain-computer interface that lets intact neural signals skip over damaged nerve pathways, restoring intention to action for people with paralysis. The company has branded its think-to-type system 'Telepathy' and is positioning it as a commercial product, not just a lab demo.
In back-to-back comments, Elon Musk predicted Neuralink could eventually reshape how the brain controls body movement and how people perceive and interact with the world, without pointing to any new clinical data, trial results, or product timeline. The statements continue a pattern of Musk previewing transformative capabilities well ahead of demonstrated evidence.
Neuralink marked two years of its Telepathy implant with 21 trial participants now steering cursors and robotic arms by thought, even reporting flashes of anticipatory control from early recipient Noland. The company backed that momentum with a $650 million Series E to fund global expansion, launched its first UK trial, GB-PRIME, with two NHS hospital systems, and hired former FDA official David McMullen to run medical affairs and regulatory strategy. It also open-sourced datarepo, the internal platform it built to wrangle the neural, imaging, and manufacturing data generated by all this activity.